Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2000
09/08/2000CA2366852A1 Transdermal device comprising non-steroidal anti-inflammatory drugs incorporated in acrylic adhesive polymer matrix
09/08/2000CA2366755A1 Method of increasing bone volume using non-naturally-occurring ep, selective agonists
09/08/2000CA2366318A1 Novel pharmaceutical, dietary and cosmetic compositions comprising zinger officinale roscoe, eicosapentaenoic acid and/or docosahexaenoic acid
09/08/2000CA2366073A1 Use of succinic acid or salts thereof and method of treating insulin resistance
09/08/2000CA2366041A1 Method for treating exercise induced asthma
09/08/2000CA2366038A1 Treating a variety of pathological conditions, including spasticity and convulsions, by effecting modulation of cns activity with isovaleramide, isovaleric acid, or a related compound
09/08/2000CA2366036A1 Method for treating copd
09/08/2000CA2365391A1 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
09/08/2000CA2365326A1 Methods of increasing bone volume using non-naturally-occurring fp selective agonists and antiresorptive compounds
09/08/2000CA2365290A1 Use of ceramides for the treatment of cystic fibrosis
09/08/2000CA2365032A1 1,2,3,4-tetrahydro-1-naphthalenamine compounds useful in therapy
09/08/2000CA2364911A1 N-substituted indolines as estrogenic agents
09/08/2000CA2364878A1 Alkenyl- and alkynyl-containing metalloprotease inhibitors
09/08/2000CA2364592A1 Genetic and epigenetic manipulation of abc transporters and ecto-phosphatases for the conference of drug resistance and for the loss of drug resistance in biological systems and methods for the detection of ecto-phosphatase inhibitors
09/08/2000CA2364169A1 Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease
09/08/2000CA2364127A1 Composition comprising a tramadol material and a selective cox-2 inhibitor drug
09/08/2000CA2364063A1 Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
09/08/2000CA2363983A1 Chemical method for making pyrithione particle dispersions
09/08/2000CA2363982A1 Pharmaceutical combination of antiviral agents
09/08/2000CA2363592A1 Oral drug delivery system
09/08/2000CA2363169A1 Inhibitors of prenyl-protein transferase
09/08/2000CA2363077A1 Methods for targeting rna molecules
09/08/2000CA2362985A1 Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase
09/08/2000CA2362911A1 Heterocyclic compounds, intermediates thereof and elastase inhibitors
09/08/2000CA2362825A1 Cdna for human methylenetetrahydrofolate reductase
09/08/2000CA2362817A1 Novel cyclic tetrapeptide derivatives and pharmaceutical use thereof
09/08/2000CA2362804A1 Crystal modification d of 8-cyano-1-cyclopropyl-7- (1s, 6s- 2,8- diazabicyclo- [4.3.0] nonan-8-yl) -6-fluoro -1,4-dihydro -4-oxo -3-quinoline carboxylic acid
09/08/2000CA2362801A1 Crystal modification c of 8-cyano-1-cyclopropyl-7-(1s, 6s-2,8- diazabicyclo-[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic
09/08/2000CA2362778A1 Inhibitors of prenyl-protein transferase
09/08/2000CA2362554A1 Utilization of polycyclic 2-amino-thiazole systems in the production of medicaments for prophylaxis or treatment of obesity
09/08/2000CA2362529A1 Jak-3 inhibitors for treating allergic disorders
09/08/2000CA2362501A1 Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists
09/08/2000CA2362494A1 Inhibitors of prenyl-protein transferase
09/08/2000CA2362493A1 Inhibitors of prenyl-protein transferase
09/08/2000CA2362489A1 Methods and compositions for the treatment of neuropathic pain, tinnitus, and other disorders using r(-)-ketoprofen
09/08/2000CA2362488A1 Methods and compositions using (-) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists
09/08/2000CA2362480A1 Pharmaceutical compositions for oral administration comprising a benzamide and at least an absorption promoter
09/08/2000CA2362364A1 Use of polycyclic thiazole systems for producing medicaments for preventing or treating obesity
09/08/2000CA2362361A1 Bupropion metabolites and methods of their synthesis and use
09/08/2000CA2361580A1 Thiazoloindolinone compounds
09/08/2000CA2361164A1 Nitroxyderivatives having antiinflammatory, analgesic and antithrombotic activity
09/08/2000CA2359754A1 Treatment or diarrhea caused by enteropathogenic escherichia coli
09/08/2000CA2330541A1 Cyclopentanone dihydropyridine compounds useful as potassium channel openers
09/07/2000DE19929647A1 Nifedipine pellets providing both rapid and sustained release comprise particulate core and nifedipine coating
09/07/2000DE19910403A1 Medicaments containing hydroxy-benzo-cyclopentabenzazepine-dione derivatives, useful as cellular hyperproliferation inhibitors, especially antitumor agents
09/07/2000DE19909979A1 Verfahren zur Herstellung von Glycokonjugaten von 20(S)-Camptothecin Process for the preparation of glycoconjugates of 20 (S) -camptothecin
09/07/2000DE19909115A1 Verwendung von Ceramiden zur Behandlung cystischer Fibrose Use of ceramides in the treatment of cystic fibrosis
09/06/2000EP1033375A1 Low-molecular heparin modification and remedy for skin ulcer
09/06/2000EP1033369A1 5H-PYRANO [2,3-d:6,5-d']DIPYRIMIDINE DERIVATIVES HAVING AN ANTIBACTERIAL, ANTIVIRAL AND IMMUNO-MODULATING ACTIVITY
09/06/2000EP1033366A2 Amide derivatives useful as Neuropeptide Y (NPY) antagonists
09/06/2000EP1033364A1 Cyano containing oxamic acids and derivatives as thyroid receptor ligands
09/06/2000EP1033133A1 Composition for treatment of diabetes and treatment of diabetes
09/06/2000EP1033132A1 Rapidly soluble drug composition
09/06/2000EP1033131A1 Composition of ingredients for a beverage having a delayed aversion effect
09/06/2000EP1033130A1 Urokinase production inhibitors, angiogenesis inhibitors and methods of prevention or treatment with both
09/06/2000EP1033129A1 Antimicrobials
09/06/2000EP1033128A2 Soft gelatin capsule manufacture
09/06/2000EP1032696A1 Vector for tissue-specific replication and gene expression
09/06/2000EP1032676A2 $i(CHLAMYDIA TRACHOMATIS) GENOMIC SEQUENCE AND POLYPEPTIDES, FRAGMENTS THEREOF AND USES THEREOF, IN PARTICULAR FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF INFECTION
09/06/2000EP1032667A2 A33-related antigens and their pharmacological uses
09/06/2000EP1032662A1 Methods and compositions for immunomodulation
09/06/2000EP1032659A1 Grafted copolymers as gene carriers
09/06/2000EP1032591A1 NOVEL pth
09/06/2000EP1032584A1 Novel 19-nor steroids substituted in position 11beta, preparation method and intermediates, application as medicines and pharmaceutical compositions containing them
09/06/2000EP1032582A1 NOVEL recJ
09/06/2000EP1032581A1 Chemical synthesis of 6-o-alkyl erythromycin a
09/06/2000EP1032580A1 Process for n-desmethylating erythromycins and derivatives thereof
09/06/2000EP1032579A1 Carbohydrate derivatives
09/06/2000EP1032578A1 Novel methylenebisphosphonic acid derivatives
09/06/2000EP1032575A1 2,3-diaryl-pyrazolo(1,5-b)pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors
09/06/2000EP1032572A2 Pyranones, method for the production and use thereof
09/06/2000EP1032571A1 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists
09/06/2000EP1032570A1 Isoquinoline derivatives and their therapeutical use
09/06/2000EP1032569A1 Imidazole derivatives, preparation and therapeutic application thereof
09/06/2000EP1032566A2 Method for the preparation of citalopram
09/06/2000EP1032562A2 Advanced glycation end-product intermediaries and post-amadori inhibition
09/06/2000EP1032561A1 Substituted oximes as neurokinin antagonists
09/06/2000EP1032560A1 Position-4 substituted 2-pyrrolidinone derivatives to reduce the level of extracellular glutamate
09/06/2000EP1032559A1 Aminoalkylphenol derivatives and related compounds
09/06/2000EP1032556A1 Pharmaceutically active compounds and methods of use
09/06/2000EP1032555A1 Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
09/06/2000EP1032424A1 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor
09/06/2000EP1032423A1 Dna encoding mammalian neuropeptide ff (npff) receptors and uses thereof
09/06/2000EP1032415A2 Composition for the treatment of allergic conditions having cysteine and serine proteinase inhibitory activity
09/06/2000EP1032414A1 Combination of hypertensin converting enzyme inhibitor with a diuretic for treating microcirculation disorders
09/06/2000EP1032410A1 Activating c1?- secretion
09/06/2000EP1032409A1 Herbal extract composition and method with immune-boosting capability
09/06/2000EP1032406A1 Reducing blood cholesterol by in vivo precipitation of bile constituents with group ii or -iii metal substances
09/06/2000EP1032405A1 Antimutagenic compositions for treatment and prevention of photodamage to skin
09/06/2000EP1032404A1 Use of sulfated oligosaccharides in lowering blood triglyceride levels
09/06/2000EP1032403A1 Nutritional supplement for cerebral metabolic insufficiencies
09/06/2000EP1032402A1 Citicoline to treat motor neuron diseases and demyelinating diseases
09/06/2000EP1032401A2 Method for inhibiting cytokine production by cells
09/06/2000EP1032400A1 Prevention of precipitated acute urinary retention
09/06/2000EP1032399A1 Progestin therapy with controlled bleeding
09/06/2000EP1032398A1 Methods for treating postmenopausal women using ultra-low doses of estrogen
09/06/2000EP1032397A1 Testosterone inhibitors and use for the protection of neurons
09/06/2000EP1032396A1 New composition of matter
09/06/2000EP1032395A1 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
09/06/2000EP1032394A1 Use of substituted 11-phenyl-dibenzazepine compounds for the treatment or prevention of sickle cell disease, inflammatory diseases characterized by abnormal cell proliferation, diarrhea and scour